Featured
Jumping hurdles to get the treatments you want is the reality for people living with MBC. Add systemic racism into the healthcare mix and it’s clear that more needs to happen, and soon, to create equity and greater diversity in one of the most important tools in the MBC toolbox: clinical trials. In this episode, we check in with Stephanie Walker, who led the BECOME project and spearheads the Black Wo(Men) Speak Symposium, patient advocate and clinical trial participant Rev. Dr. Tawana Davis, and Patient Navigator Valarie Worthy. How does systemic racism affect what Black patients learn about MBC clinical trials? And how can those who need it most break down barriers to the best care?
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.
There’s a FDA- approved diagnostic imaging agent developed to comprehensively evaluate estrogen receptor-positive (ER+) lesions in recurrent or metastatic breast cancer as an adjunct to biopsy. By creating a “whole-body” picture of ER+ lesions, Cerianna may be a helpful diagnostic tool in helping oncologists better determine the most appropriate course of treatment. Learn more in this episode.
Celebrate OMBCL’s 100th episode and National Family Caregiver Month by listening to our candid conversations with three committed and courageous caregivers.
While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.
We Remember honors all who died from metastatic breast cancer over the past year—parents, children, spouses and partners. In this episode, the MBC community gives voice to both the grief and the love that endures after each death.
MSK’s Dr. Shanu Modi, lead investigator on the DESTINY-Breast04 trial, talks with the Our MBC Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.
The DESTINY-Breast04 trial at ASCO 2022 introduced many people to the term “HER2-low.” But how do you know if you’re HER2-low? In this episode, with the help a breast pathologist and a clinical oncologist we dive into this subtype and what it means to us.
Lisa Laudico, who created and spearheaded the Our MBC Life podcast series, died on August 6, 2022 from MBC. In this episode, Lisa’s friends, family, and colleagues remember her amazing life and celebrate the many ways she fostered connection, resilience, and hope throughout the MBC community.
The Our MBC Life senior producers and co-hosts, Victoria Goldberg and Natalia Green join Anne Woodward in a conversation about the upcoming season 5 of the podcast and some new things the team is doing and exciting details for very special giveaways for the Our MBC Life merchandise.
Is laughter good medicine? These breast cancer survivors/thrivers say: Yes!